The US Department of Defense has removed WuXi AppTec, a Chinese contract maker and developer of medicines, from its list of "Chinese military companies" operating in the United States. The notice, dated 5 November 2026 and published in the Federal Register, the US government's official journal, on 10 November, says the removal complies with a court order of 7 August 2026 and is made "without prejudice to relisting the company on additional or supplementary grounds". A second Chinese company added to the list at the same time, the gene-sequencing firm Novogene, has now gone to the same court.1 2
What the list is
Section 1260H of the 2021 defence authorisation act requires the Defense Secretary to publish a list of Chinese military companies each year until the end of 2030. The latest list appeared in the Federal Register on 10 June 2026.1
The list is not a sanctions list and not an export-control list. Its effects come through government purchasing. According to an analysis by the law firm Greenberg Traurig, the department has been barred since 30 June 2026 from contracting directly with a listed company, and from 30 June 2027 the bar extends to goods and services that contain a listed company's products anywhere in the supply chain. The June update added about 65 entities, for a total of about 200, among them three biotechnology companies: WuXi AppTec, Novogene and Complete Genomics.3
Why the court intervened
WuXi AppTec sued in the federal district court in Washington. On 7 August 2026 the court issued a preliminary injunction, an interim order that stops a measure while the case is decided, forbidding the department to enforce or give effect to the designation.1 3
Greenberg Traurig's account of the ruling says the department had justified the listing in one sentence, citing indirect state ownership and indirect links to China's defence industry regulator and the army, and that the court found each ground factually deficient. A 5.32% shareholding the department cited turned out to describe the weight of the stock in a state aviation fund's portfolio, while that fund's actual share of WuXi AppTec was nearer 0.001%. The court also accepted that the company had suffered harm that could not be undone, since customers and suppliers had cancelled contracts within weeks of the listing.3
The order is interim, and the notice says so. The department has complied by delisting, and it has kept open the option of listing the company again on a corrected record.1 3
How the company and Chinese press read it
WuXi AppTec told investors on 10 November 2026 that it had learnt of the decision the day before. The Shanghai business daily Yicai quotes the announcement.4
此次移除使公司不再因1260H名单而承受进一步的不利影响。
This removal means the company no longer bears further adverse effects from the 1260H list.4
Yicai's interest is in a second US list. The BIOSECURE Act, passed in December 2025, bars federal agencies from buying from "biotechnology companies of concern" and from contractors that use them. The White House budget office must publish its first list of such companies by 18 December 2026. A company on the 1260H list can be placed on it by that route; a company that is not must be designated separately, after written notice and a 90-day period to respond. Yicai reports that WuXi AppTec's management said on 27 October it had received no such notice, and the paper judges a separate designation unlikely for now. The company's revenue for January to September 2026 was 45.5 billion yuan, and North America is its largest market.3 4
Novogene's suit
Novogene announced on 5 November 2026 that it and its US subsidiary had sued the Defense Department in the same court, asking it to declare the designation unlawful and set it aside, and had applied for a preliminary injunction. The Chinese financial news service Cailian Press reports the announcement.2
公司被列入1260H清单,并不意味着公司已被列入任何制裁或出口管制名单。
The company's inclusion in the 1260H list does not mean that it has been placed on any sanctions or export-control list.2
The company said the listing had affected its work with some US customers and that its business as a whole was operating normally. A chronology kept by Tsinghua University's PBC School of Finance gives the case number as 1:2026cv03880.2 5
The US government has given no public reason for the delisting beyond the court order cited in its notice.1
Next
The budget office's first list under the BIOSECURE Act is due by 18 December 2026. No ruling on Novogene's application has been reported, and the order in WuXi AppTec's favour is an interim one, not a final judgment.3 2